Clinical trials: Sitagliptin, completed
Type 1 Diabetes, Hypoglycemia
Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery
Hypoglycaemia is a well-known complication of insulin treated diabetes. The counterregulatory response to hypoglycaemia, with glucagon as the most important mediator, is initially diminished within a few years of onset of Type 1…
- Trial name
- DARE (NCT01272583)
- Testing
- Sitagliptin
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetes Mellitus, Liver Transplant; Complications
Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
Patients with pre-transplantation type 2 diabetes (T2D) and new-onset diabetes post liver transplantation (NODAT) are managed with multiple doses of subcutaneous insulin (MSI) following liver transplantation.
- Trial name
- Dapa-LiT (NCT05042505)
- Testing
- Dapagliflozin 10Mg Tab, Sitagliptin 100mg
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Platelet Aggregation During Acute Myocardial Infarction
DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function
Cardiovascular events are the main cause of mortality in diabetic patients ,on the other hand,during an acute myocardial infarction(AMI),hyperglycemia increases mortality and is related to different pathophysiologic processes.
- Trial name
- NCT02377388
- Testing
- sitagliptin OR saxagliptin
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- University of Sao Paulo General Hospital
Type 2 Diabetes
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and…
- Trial name
- NCT00806520
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- HealthPartners Institute
Diabetes Mellitus, Type 2
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
- Trial name
- NCT00631488
- Testing
- MK-0893, Sitagliptin, Metformin
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes
In a prospective, randomized case-controlled study, the investigators hope to demonstrate a positive correlation of plasma levels of EPA and DHA as well as fish intake with the HbA1c-lowering effect of sitagliptin but not with…
- Trial name
- DIET (NCT02312063)
- Testing
- Sitagliptin, Glimepiride
- Where
- 2 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Kansai Electric Power Hospital
Type 2 Diabetes Mellitus
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00127192
- Testing
- sitagliptin phosphate
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)
A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.
- Trial name
- NCT00704132
- Testing
- Comparator: sitagliptin phosphate
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the…
- Trial name
- NCT05768945
- Testing
- Semaglutide, DPP-4 inhibitor
- Where
- United States
- Volunteers
- 742,670 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Diabetes
Replication of the GRADE Diabetes Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05099198
- Testing
- Sitagliptin, Glimepiride
- Where
- United States
- Volunteers
- 6,403 people
- Sponsor
- Brigham and Women's Hospital
Kidney Transplant, Type 2 Diabetes
Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant
This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.
- Trial name
- NCT00466518
- Testing
- Administration of sitagliptin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Oklahoma
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Type 1 Diabetes, Monogenic Diabetes
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study
The purpose of this study is to evaluate the efficacy of adding oral hypoglycemic agents (OHA) to existing insulin treatment in monogenic variant carriers of the Joslin 50-Year Medalist Study ("Medalists"), who are characterized…
- Trial name
- NCT04409795
- Testing
- Metformin Extended Release Oral Tablet, Sitagliptin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Joslin Diabetes Center
Type 2 Diabetes Mellitus
Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)
A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00449930
- Testing
- sitagliptin phosphate, Comparator: metformin hydrochloride
- Volunteers
- 1,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Insufficiency, Hemodialysis
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
A study to evaluate the effect of kidney disease, from mild to severe disease, on a diabetes medication
- Trial name
- NCT00418366
- Testing
- MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin and placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin monotherapy (i.e.…
- Trial name
- NCT01106677
- Testing
- Canagliflozin, Sitagliptin, Metformin immediate release
- Where
- 125 sites in United States, Argentina and 20 more
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124495
- Testing
- Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Diabetes Mellitus, Type 2
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) and sitagliptin (25 mg qd) when used in patients with type 2 diabetes mellitus(T2DM) and…
- Trial name
- NCT00616811
- Testing
- vildagliptin, Sitagliptin
- Where
- 79 sites in United States
- Volunteers
- 148 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
- Trial name
- NCT00722371
- Testing
- Sitagliptin phosphate, Pioglitazone hydrochloride, Metformin
- Volunteers
- 1,615 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC